Policy | Funding | Influence
Insights for changemakers on navigating government opportunities.
G2G Bio Bulletin – April 20, 2026
Federal Legislative Updates Ohio Legislative Updates G2G Blog Back to All Posts Updates from Washington Congress: Both chambers reconvened this week. FY 2027 Appropriations: House appropriators intend to rapidly complete all twelve…
G2G Bio Bulletin – April 13, 2026
Federal Legislative Updates Ohio Legislative Updates G2G Blog Back to All Posts Updates from Washington Congress: The House and Senate were on recess this past week, and will reconvene on…
G2G Bio Bulletin – April 7, 2026
Federal Legislative Updates Ohio Legislative Updates G2G Blog Back to All Posts Funding & Other Opportunities New ARPA-H Program: Systematic Targeting Of MicroPlastics (STOMP). Highlights: Across two phases STOMP aims…
G2G Bio Bulletin – March 31, 2026
Federal Legislative Updates Ohio Legislative Updates G2G Blog Back to All Posts April 3, 2026 Update The SBIR/STTR Reauthorization Bill (S. 3971) was presented to President Trump yesterday. This means: If he…
G2G Bio Bulletin – March 23, 2026
Committee leaders from both parties have taken actions and floated proposals to address healthcare costs and improve access to medicines.
G2G Bioscience Bulletin – March 16, 2026
G2G with Women’s Health Advocates (WHA) the Endo & Adeno Coalition, Krampz Wellness and partners organized an Endometriosis & Adenomyosis Capitol Hill Day on March 10 and an accompanying Congressional Briefing on March 9 to advocate for better research and care for patients.
G2G Bio Bulletin – March 8, 2026
On Tuesday, the Senate Committee on Commerce, Science & Transportation’s Science Subcommittee convened a hearing on applications of AI. Witnesses were affiliated with RadAI, Siemens, Agility Robotics and the Brookings Institution.
G2G Bio Bulletin – March 1, 2026
G2G’s DC team was on Capitol Hill this week, alongside dozens of advocates and stakeholders from across the country.
G2G Bio Bulletin – February 21, 2026
The Congressionally Directed Medical Research Programs (CDMRP) has released pre-announcements for the FY 26 Spinal Cord Injury, ALS, Arthritis, Ovarian Cancer, Pancreatic Cancer and Tick-Borne Disease Research Programs.
G2G Bio Bulletin – February 14, 2026
The Congressionally Directed Medical Research Programs (CDMRP) has released pre-announcements for FY26 Breast Cancer Research Program (BCRP) and Lupus Research Program (LRP)
